Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study

The relationship between gains in bone mineral density (BMD) in the hip and the incidence of vertebral fractures in the MOVER study was examined. Japanese patients from the ibandronate and risedronate treatment groups whose hip BMD had increased during the 3-year treatment period were classified int...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Calcif Tissue Int
Main Authors: Hagino, Hiroshi, Yoshida, Seitaro, Hashimoto, Junko, Matsunaga, Masayuki, Tobinai, Masato, Nakamura, Toshitaka
פורמט: Artigo
שפה:Inglês
יצא לאור: Springer US 2014
נושאים:
Original Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4239781/
https://ncbi.nlm.nih.gov/pubmed/25377907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00223-014-9927-7
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים